Biogen begins phase 3 paediatric study of Omaveloxolone to treat Friedreich ataxia: Cambridge, Mass Saturday, June 21, 2025, 11:00 Hrs [IST] Biogen Inc, a leading biotechnology co ...

As the saying goes, “If you don’t laugh, you’ll cry.” Biogen and ad agency 21Grams took that mantra to heart with their Gold ...

The trial aims to assess the safety, pharmacodynamics, efficacy, and pharmacokinetics of the therapy in nearly 255 subjects.

Biogen Inc. (NASDAQ: BIIB) lost strength in Wednesday trading, after the Cambridge, Mass.-based company announced the initiation of dosing in the BRAVE study, a global Phase 3 clinical trial. The ...

Global Phase 3 BRAVE study will evaluate the efficacy and safety of omaveloxolone in children 2 to BRAVE study will explore the potential of omaveloxolone to address the critical unmet need of the ped ...

Global Phase 3 BRAVE study will evaluate the efficacy and safety of omaveloxolone in children 2 to <16 years old with Friedreich ataxia, a rare neurodegenerative disorderBRAVE study will explore the ...

To create this list of companies, we cross-referenced the HRC’s 2025 Corporate Equality Index (CEI) — a national benchmarking tool that evaluates companies on policies, benefits, and workplace ...

The winning work from Ogilvy Shanghai answered the question of how to promote Viagra in a country where pharma ads are banned ...

After Biogen failed with a takeover bid in January, Supernus has swooped in to acquire the postpartum depression pill ...

What Is Fueling This Impressive Growth In The Chemotherapy-Induced Neutropenia Treatment Market? The reasons are manifold and include factors such as increasing cancer incidence rates, growing ...

When asked why Biogen decided to sell the rights to the drug ... A study published in JAMA Health Forum found that biosimilar prices are typically 15% to 35% lower than their brand-name counterparts.